AIM IMMUNOTECH INC (AIM)
AMEXHealth CareBiotechnologySnapshot 2026-11-04
$0.16+0.19%
Close 2026-11-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · AIM
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -35.2% |
| Our one-year growth estimate | diamond | 4.5% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 39.7 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
AIM — litigation filed
Dated 2026-11-05
Regulation FD Disclosure. Furnished herewith as Exhibits 99.1 and 99.2, respectively, are a Corporate Presentation of AIM ImmunoTech Inc. (the “Company”) titled “The Ampligen Opportunity” and a press release issued by the Company on November 5, 2026. The information furnished under this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilit…
Why it matters: AIM has started Phase 3 study design work, but the company is loss-making and has raised capital. A clear plan and enough funding matter for trial progress.
Watch forAIM names a Phase 3 start window, trial design, and funding plan, with no reported delay in drug supply.
Also watch forAIM delays the Phase 3 plan, reports a drug supply gap, or says current funds cannot support the trial.
Why it matters: This is the first key test of Ampligen with durvalumab in pancreatic cancer. The results can guide the planned Phase 3 study.
Watch forAIM reports clinical benefit data in Q1 2027. The results support the treatment's benefit and safety.
Also watch forAIM reports no clinical benefit, a safety concern, or a delay beyond Q1 2027.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$274 on $10,000 · ±2.7% | How much price usually moves either way. |
| Bad day | $664 loss on $10,000 · 6.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,446 loss on $10,000 · 94.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.